In 2006, GlaxoSmithKline Inc. (GSK), a world leading research-based pharmaceutical company committed to developing innovative medicines and vaccines, awarded SNC-Lavalin a contract for the renovation of GSK Biologicals Quebec City Vaccine Production Facility in Ste-Foy, Québec.
Meeting a critical need
SNC-Lavalin provided architectural/engineering, procurement, construction management, and validation and commissioning services for facility modifications and the addition of new equipment to raise production capacity to up to 75 million vaccine doses for the 2007 flu season campaign. The project also included improvements to the existing facility to meet the NCB2+ requirements defined by the World Health Organization for the production of influenza vaccines.
An award-winning achievement
SNC-Lavalin received a Prix Léonard in the Industry category from the Association of consulting engineers of Quebec for the project’s exceptional design, execution and sustainable development elements.